Arizona 2025 2025 Regular Session

Arizona Senate Bill SB1230 Comm Sub / Analysis

Filed 02/06/2025

                    Assigned to HHS & APPROP 	FOR COMMITTEE 
 
 
 
 
ARIZONA STATE SENATE 
Fifty-Seventh Legislature, First Regular Session 
 
FACT SHEET FOR S.B. 1230 
 
marijuana; clinical research trials 
Purpose 
Requires, rather than allows, monies in the Medical Marijuana Fund (Fund) to be used to 
provide grants for marijuana clinical trials and for the Arizona Biomedical Research Center 
(ABRC) to provide up to $5,000,000 annually from the Fund for five consecutive years to 
administer and award competitive grants. Contains requirements for enactment for initiatives and 
referendums (Proposition 105). 
Background 
In 2010, Arizona voters approved the Arizona Medical Marijuana Act to establish a 
regulatory system overseen by the Department of Health Services (DHS) that allows a dispensary 
to dispense a permissible amount of medical marijuana to a qualifying patient with a medical 
marijuana registry identification card (A.R.S. Title 36, Chapter 28.1). Fees collected from the sale 
of medical marijuana are deposited in the Fund before being allocated to outlined entities. The 
Fund consists of collected fees, civil penalties and private donations, which may be used to provide 
grants for marijuana clinical trials (A.R.S. § 36-2817).  
Current statute requires the ABRC to provide competitive grants from monies in the Fund 
for marijuana clinical trials that are approved by the U.S. Food and Drug administration (FDA) for 
evaluating the safety and efficacy of using marijuana in humans and researching the impacts of 
marijuana interactions with prescription drugs, nonprescription drugs and illicit drugs. Clinical 
trials funded by ABRC must be: 1) conducted by Arizona-based researchers from nonprofit 
organizations or universities; 2) approved by the FDA, the U.S. Drug Enforcement Administration 
and an institutional review board; and 3) be publishable in peer-reviewed medical and public health 
journals. The ABRC must prioritize funding opportunities for randomized controlled clinical trials 
that study the treatment of autism, epilepsy, post-traumatic stress disorder and pain. The ABRC 
may provide up to $5,000,000 annually for five consecutive years from the Fund to administer and 
award competitive grants. The ABRC may not use more than five percent of these monies for 
administrative purposes (A.R.S. § 36-2822). 
There is no anticipated fiscal impact to the state General Fund associated with this 
legislation. 
Provisions 
1. Requires, rather than allows, monies in the Fund to be used to provide grants for marijuana 
clinical trials.  FACT SHEET 
S.B. 1230 
Page 2 
 
 
2. Requires, rather than allows, the ABRC to provide up to $5,000,000 annually for five 
consecutive years from the Fund to administer and award competitive grants for marijuana 
clinical trials. 
3. Makes technical changes. 
4. Requires for enactment the affirmative vote of at least three-fourths of the members of each 
house of the Legislature (Proposition 105). 
5. Becomes effective on the general effective date. 
Prepared by Senate Research 
February 3, 2025 
MM/AO/slp